.

Professor Michael J. Tisdale

 

Professor of Cancer Biochemistry

School of Life & Health Sciences
Aston University
Aston Triangle
Birmingham B4 7ET
UK

email: M.J.Tisdale@aston.ac.uk
telephone: +44 (0) 121 204 4021
fax: +44 (0) 121 204 3743

Research Theme

Chronic and Communicable Conditions

Research Centre

Aston Research Centre for Healthy Ageing (ARCHA) 

Member of the Pharmacy and Biology Teaching Programmes
tisdalmj-1.jpg

Profile

I joined the Cancer Research Campaign Experimental Chemotherapy Group in the Department of Pharmacy at Aston University as Senior Research Fellow in October 1980.  Prior to that I spent 8 years as Lecturer in the Department of Biochemistry at St Thomas’s Hospital Medical School, University of London, one year as Scientific Officer at Rothamstead Experimental Station, Harpenden and one year as MRC Fellow at the Institute of Cancer Research.

Qualifications

• BSc (lst Class Honours) (Chemistry), Hull, 1967
• PhD (Chemistry), London, 1970
• DSc (Cancer Biochemistry), London, 1983

 Career History

• 1989–date: Professor of Cancer Biochemistry, Aston University
• 1992-95: Head of Department, Pharmaceutical and Biological Sciences, Aston  University
• 1984-89: Reader, Department of Pharmaceutical Sciences, Aston University 
• 1981-84: Senior Research Fellow, CRC Experimental Chemotherapy Group, Aston  University
• 1972-81: Lecturer Department of Biochemistry, St Thomas’s Medical School
• 1971-72: Scientific Officer, Rothamstead Experimental Station
• 1970-71: MRC Fellow, Institute of Cancer Research

Teaching activity

Mainly related to cancer causation, biology treatment and associated conditions e.g. cachexia.

Modules: PH3 CM1, PH1 CM1, BY3 CM1, BY1 CM1, BY2 BD1, PH3 MC1

Research Interests

Cancer cachexia, mechanism and treatment.  Treatment of obesity and type 2 diabetes.

Specifically:

• Signal transduction pathways involved in muscle catabolism by proteolysis-inducing factor (PIF)
• Cloning and sequencing of cellular receptor for PIF
• Cloning and expression of PIF
• Investigation of antibodies to the PIF receptor as anticachectic agents
• Action of eicosapentaenoic acid (EPA) in preventing muscle catabolism by PIF
• Role of EPA in attenuating muscle catabolism in catabolic states other than cancer cachexia
• Clinical evaluation of EPA in the treatment of cancer cachexia

Research Funding

 

Awarding Body

Title of Project

Amount (£)

Dates

Halsa Pharmaceuticals

Evaluation of zinc-alpha 2-glycoprotein for the treatment of obesity

220,000

2008-2010

Bioneris

Anticachectic activity of a novel agent

135,000

2006-2009

Ross Products Division

Effect of ingredients in an animal model of cachexia

490,536

2002-2008

British Technology Group

Studies on the PIF receptor

74,986

2005

Novartis Medical Nutrition

Investigation into the mechanism for depression of protein synthesis in cancer

152,404

2004-2007

 

Ark Therapeutics

To determine whether angiotensin II has a direct effect on muscle protein degradation

142, 528

2003-2005

Bayer Healthcare

The potential therapeutic use of zinc-alpha2-glcyoprotein for obesity and type II diabetes

196,868

2002-2004

Lustgarten Foundation

Cloning and expression of a muscle receptor for a cancer-cachectic factor

50,655

2003

Novartis Consumer Health

Studies on cancer cachexia

131,964

2003-2004

Publications


• Russell ST, Rajani S, Dhadda RS, Tisdale MJ (2009) Mechanism of induction of muscle protein loss by hyperglycaemia.  Exp. Cell. Res. 315, 16-25.
• Eley HL, McDonald PS, Russell ST, Tisdale MJ (2008) Inhibition of activation of dsRNA-dependent protein kinase and tumour  growth inhibition.  Cancer Chemother Pharmacol available online DOI 10.1007/s00280-008-0782-y.
• Tisdale MJ (2008) Catabolic mediators of cancer cachexia.  Current Opinion in Supportive and Palliative Care 2, 256-261.
• Eley HL, Russell ST, Tisdale MJ (2008) Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor and angiotensin II by -hydroxy--methylbutyrate.  Am. J. Physiol. Endocrinol. Metab. 295, E1409-E1416.

• Eley HL, Russell ST, Tisdale MJ (2008) Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor and angiotensin II by -hydroxy--methylbutyrate.  Am. J. Physiol. Endocrinol. Metab. 295, E1417-E1426.
• Khal J, Tisdale MJ (2008) Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid.  Biochem. Biophys. Res. Commun. 375, 238-240.
• Eley HL, Russell ST, Tisdale MJ (2008) Role of the dsRNA-dependent protein kinase (PKR) in the attenuation of protein loss from muscle by insulin and insulin-like growth factor-I (IGF-I).  Mol. Cell. Biochem. 313, 63-69.
• Yano CL, Ventrucci G, Field WN, Tisdale MJ, Gomes-Marcondes MCC (2008)
 Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes.  BMC. Cancer 8, 24.
• Russell ST, Eley HL, Wyke SM, Tisdale MJ (2008) Involvement of phosphoinositide 3-kinase and Akt in the induction of muscle protein degradation by proteolysis-inducing factor.  Biochem. J. 409, 751-759.
• Eley HL, Skipworth RJE, Deans DAC, Fearon KCH, Tisdale MJ (2008) Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2 may signal skeletal muscle atrophy in weight losing cancer patients.  Br. J. Cancer 98, 443-449.
• Todorov PT, Wyke SM, Tisdale MJ (2007) Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle .  Cancer Res. 67, 11419-11427.
• Tisdale MJ (2007) Is there a common mechanism linking muscle wasting in various disease types?  Current Opinion in Supportive and Palliative Care 1, 287-292.
• Eley HL, Russell ST, Baxter JH, Mukherji P, Tisdale MJ (2007) Signaling pathways initiated by -hydroxy--methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli.  Am. J. Physiol. Endocrinol. Metab. 293, E923-E931.
• Eley HL, Russell ST, Tisdale MJ (2007) Effect of branched-chain amino acids on muscle atrophy in cancer cachexia.  Biochem. J 407, 113-120.
• Russell ST, Eley HL, Tisdale MJ (2007) Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II.  Cell. Sig. 19, 1797-1806.
• Russell ST, Eley H, Tisdale MJ (2007) Mechanism of attenuation of angiotensin-II-induced protein degradation by insulin-like growth factor-I (IGF-I).  Cell. Sig. 19, 1583-1595.
• Eley HL, Russell ST, Tisdale MJ (2007) Attenuation of muscle atrophy in a murine model of cachexia by inhibition of dsRNA-dependent protein kinase.  Br. J. Cancer 96, 1216-1222.
• Eley HL, Tisdale MJ (2007) Skeletal muscle atrophy: A link between depression of protein synthesis and increase in degradation.  J. Biol. Chem. 282, 7087-7097.
• Bhogal AS, Lorite ML, Tisdale MJ (2006) Changes in nucleic acid and protein levels in atrophying skeletal muscle in cancer cachexia.  Anticancer Research 26, 4149-4154.
• Bing C, Russell S, Becket E, Pope M, Tisdale MJ, Trayhurn P, Jenkins JR (2006)
 Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice.  Br. J. Cancer 95, 1028-1037.
• Fearon KCH, Barber MD, Moses AG, Ahmedzani SH, Tisdale MJ, Taylor GS, Murray GD (2006) Double-blind, placebo controlled, randomised study of eicosapentaenoic acid diester in patients with cancer cachexia.  J. Clin. Oncol. 24, 3401-3407.
• Deans DAC, Wigmore SJ, Gilmour H, Tisdale MJ, Fearon KCH, Ross JA  (2006)
 Expression of the proteolysis-inducing factor core peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastro-oesophageal malignancy.  Br. J. Cancer 94, 731-736.
• Wyke SM, Tisdale MJ (2006) Induction of protein degradation in skeletal muscle by a phorbol ester involves upregulation of the ubiquitin-proteasome proteolytic pathway. Life Sciences 78, 2898-2910.
• Russell ST, Wyke SM, Tisdale MJ (2006) Mechanism of induction of muscle protein degradation by angiotensin II.  Cell.Sig. 18, 1087-1096.
• Russell ST, Sanders PM, Tisdale MJ (2006) Angiotensin II directly inhibits protein synthesis in murine myotubes Cancer Lett. 231, 290-294.
• Khal J, Wyke SM, Russell ST, Hine AV, Tisdale MJ (2005) Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia.  Br. J. Cancer 93, 774-780.
• Khal J, Hine AV, Fearon KCH, Dejong CHC, Tisdale MJ (2005) Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. 37, 2196-2206.
• Sanders PM, Russell ST, Tisdale MJ (2005) Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia.  Br. J. Cancer 93, 425-434.
• Smith HJ, Khal J, Tisdale MJ (2005) Downregulation of ubiquitin-dependent protein degradation in murine myotubes during hyperthermia by eicosapentaenoic acid. Biochem. Biophys. Res. Commun. 332, 83-88.
• Russell ST, Tisdale MJ (2005) Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia.  Prostaglandins Leukotrienes and Essential Fatty Acids 72, 409-414.
• Russell ST, Tisdale MJ (2005) The role of glucocorticoids in the induction of zinc-2-glycoprotein expression in adipose tissue in cancer cachexia.  Br. J. Cancer 92, 876-881.
• Wyke SM, Tisdale MJ (2005) NF-B mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle.  Br. J. Cancer 92, 711-721. 

• Smith HJ, Mukerji P, Tisdale MJ (2005) Attenuation of proteasome-induced proteolysis in skeletal muscle by -hydroxy--methylbutyrate in cancer-induced muscle loss.  Cancer Res. 65, 277-283.
• Chand A, Wyke SM, Tisdale MJ (2005) Effect of cancer cachexia on the activity of tripeptidyl-peptidase II in skeletal muscle.  Cancer Lett. 218, 215-222.
• Wyke SM, Khal J, Tisdale MJ (2005) Signalling pathways in the induction of proteasome expression by proteolysis-inducing factor in murine myotubes.  Cell. Sig. 17, 67-75.
• Beck SA, Tisdale MJ (2004) Effect of cancer cachexia on triacylglycerol / fatty acid substrate cycling in white adipose tissue.  Lipids 39, 1187-1189.
• Smith HJ, Wyke SM, Tisdale MJ (2004) Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by -hydroxy--methylbutyrate.  Cancer Res. 64, 8731-8735.
• Wynter P, Russell ST, Tisdale MJ (2004) Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs.  In Vivo 18, 543-548.
• Wyke SM, Russell ST, Tisdale MJ (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-B activation.  Br. J. Cancer 91, 1742-1750.
• Lattman E, Kinchington D, Dunn S, Singh H, Ayuko W, Tisdale MJ (2004)
 Cytotoxicity of 3, 4-dihalogenated 2(5H)-furanones.  J. Pharm. Pharmacol. 56, 1163-1170.
• Sanders PM, Tisdale MJ (2004)
 Effect of zinc-2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue.  Cancer Lett. 212, 71-81.
• Smith HJ, Greenberg NA, Tisdale MJ (2004)
 Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice.  Br. J. Cancer 91, 408-412.
• Smith HJ, Wyke SM, Tisdale MJ (2004)
 Role of protein kinase C and NF-B in proteolysis-inducing factor-induced proteasome expression in C2C12 myotubes.  Br. J. Cancer 90, 1850-1857.
• Sanders PM, Tisdale MJ (2004)
 Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage.  Br. J. Cancer 90, 1274-1278.
• Zhao K, Wang Y, Zhao L, Ji Z, Li D, Schwalbe CH, Tisdale MJ (2004) Synthesis and cytotoxicity of a novel 1-alkylaminomethyl-2, 4-diaryl-butadiene-1, 3 fragment integrated with cyclohex (pent) enes.  IL FARMACO 59, 373-379.
• Russell ST, Zimmerman TP, Domin BA, Tisdale MJ (2004)
 Induction of lipolysis in vitro and loss of body fat in vivo by zinc-2-glycoprotein.  Biochem. Biophys. Acta 1636, 59-68.
• Bing C, Bao Y, Jenkins J, Sanders P, Manjeri M, Cinti S, Tisdale MJ, Trayhurn P (2004)
 Zinc-2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia.  Proc. Natl. Acad. Sci. USA 101, 2500-2505.
• Fearon KCH, von Meynefeldt MF, Moses AGW, van Geenen R, Roy A, Gouma DJ, Giacosa A, van Gossum A, Bauer J, Barber MD, Aaronson NK, Voss AC, Tisdale MJ (2003)
 Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.  Gut. 52, 1479-1486.
• Smith HJ, Tisdale MJ (2003) Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes.  Br. J. Cancer 89, 1783-1788.
• Whitehouse AS, Tisdale MJ (2003)
 Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-B.  Br J Cancer 89, 1116-1122.
• Whitehouse AS, Khal J, Tisdale MJ (2003)
 Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway.  Br J Cancer 89, 737-745.
• Lattman E, Ayuko W, Kinchington D, Langley CA, Singh H, Karimi L, Tisdale MJ (2003)
Synthesis and evaluation of 5-arylated 2(5H)-furanones and 2-arylated pyridazin-3(2H)-ones as anti-cancer agents.  Pharm. Pharmacol.  Lett. 55, 1259-1265.
• Simpson J, Forrester R, Billington DC, Rathbone DL, Tisdale MJ (2003)
 Effect of catechol derivatives on cell growth and lipoxygenase activity Bioorg. Med. Chem. Lett. 13, 2435-2439. 

Invited Reviews:

Clinical anticachexia treatments.  Nutrition in Clinical Practice 21, 168-174, 2006.

Molecular pathways leading to cancer cachexia.  Physiology (Bethesda) 20, 340-348, 2005.

Cancer cachexia.  Langenbecks Arch. Surg. 389, 299-305, 2004.

Pathogenesis of cancer cachexia.  J. Supportive Oncology 1, 159-168, 2003.

The ‘cancer cachectic factor’.  Support Care Cancer 11, 73-78, 2003.

Cachexia in cancer patients Nature Reviews Cancer 2, 862-871, 2002.

Biochemical mechanisms of cellular catabolism Current Opinion in Clinical Nutrition and Metabolic Care 5, 401-405, 2002.

Mechanisms of tissue catabolism and reversal in cancer Aktuel Ernaehr. Med. 26, 1-5, 2001.

Cancer anorexia and cachexia Nutrition 17, 438-442, 2001.

Loss of skeletal muscle in cancer: Biochemical mechanisms Front. Biosci. 6, D164-D174, 2001.

Catabolism of skeletal muscle proteins and its reversal in cancer cachexia In: Nestlé Nutrition Workshop Series Clinical and Performance Program, Vol 4.  Cancer and Nutrition: Prevention and Treatment (eds J. Mason and G. Nitenberg) pp 135-146, 2000.  S. Karger, Switzerland.

Metabolic abnormalities in cachexia and anorexia Nutrition 16, 1013-1014, 2000.

Protein loss in cancer cachexia Perspectives: Biomedicine Science 289, 2293-2294, 2000.

Book Chapters:

Catabolism of skeletal muscle proteins and its reversal in cancer cachexia In: Nestlé Nutrition Workshop Series Clinical and Performance Program, Vol 4.  Cancer and Nutrition: Prevention and Treatment (eds J. Mason and G. Nitenberg) pp 135-146, 2000.  S. Karger, Switzerland.

Supportive Care: Cachexia and anorexia syndrome.  In: Pancreatic Cancer (eds: D.D. Von Hoff, D.B. Evans and R.H. Hruban).  Chapter 35. pp 499-511, Jones and Bartlett, 2005.

Protein metabolism in cachexia.  In: Cachexia and Wasting.  A Modern Approach (ed. G. Mantovani) Chapter 5.2 pp 185-190, Springer-Verlag, Italy, 2006.

Proteolysis-inducing factor in cancer cachexia.  In: Cachexia and Wasting.  A Modern Approach (ed. G. Mantovani) Chapter 9.4. pp 483-488, Springer-Verlag, Italy, 2006.

Cachexia in Clinical Oncology (4th edition) (eds M. Abeloff. M. Kasten, J. Armitage, G. McKenna and J. Niederhuber) Chapter 38 pp 591-598, Elsevier, 2008.

Supportive Care: Cachexia, anorexia syndrome. In Pancreatic Cancer (eds A.M. Lowy, S.D. Leach and P.A. Phillip) Chapter 26 pp 449-462, Springer, 2008.





  

 

Employable Graduates; Exploitable Research